We are international
• treatment options TEXT SIZE   
imf research grants archive    back

Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma
Aaron Schimmer, MD, PhD, FRCPC
Princess Margaret Hospital
Ontario Cancer Institute
Toronto, ON, Canada

Be the first to comment

 related articles
Bone marrow microenvironment and multiple myeloma chemotherapy optimization
Characterization and preclinical evaluation of NKT cells in multiple myeloma
Mesenchymal cell cytotherapy for multiple myeloma
MMSET and epigenetic control in t(4;14) myelomas
Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins
Reolysin: a novel reovirus-based therapy for multiple myeloma